Reconstruction Kinetics of γδ T Cells After Unrelated Cord Blood Transplantation
1 other identifier
observational
100
1 country
1
Brief Summary
The primary objective is to investigate the correlation between specific patterns of γδ T cell reconstitution after umbilical cord blood transplantation and key clinical outcomes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Oct 2025
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 9, 2025
CompletedFirst Submitted
Initial submission to the registry
August 20, 2026
CompletedFirst Posted
Study publicly available on registry
August 24, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
October 1, 2030
August 24, 2026
October 1, 2025
1.1 years
August 20, 2026
August 20, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Reconstitution level of γδ T cells
The reconstitution level of γδ T cells in peripheral blood will be measured by flow cytometry at 1, 2, 3, 6, 9, and 12 months after umbilical cord blood transplantation. The outcome is measured as the absolute cell count per microliter of blood and/or the percentage of γδ T cells within total lymphocytes.
1 year
Secondary Outcomes (5)
Overall Survival (OS)
1-5 year
Leukemia-free Survival (LFS)
1-5 year
GRFS (Graft-versus-Host Disease-free, Relapse-free Survival)
1-2 year
Cumulative Incidence of Relapse
1-5 year
Incidence of Acute Graft-versus-Host Disease (aGVHD) or Chronic Graft-versus-Host Disease (cGVHD)
100 days, 1-2 year
Study Arms (1)
Immune reconstitution after umbilical cord blood transplant
This is the single cohort of the study, comprising all patients who received an allogeneic umbilical cord blood transplant. The kinetics of γδ T cell and other immune cells reconstitution will be analyzed for the entire cohort.
Interventions
Allogeneic umbilical cord blood transplantation as a standard treatment for underlying hematological diseases.
Eligibility Criteria
The study population will consist of patients undergoing their first allogeneic unrelated donor umbilical cord blood transplantation as standard treatment for their underlying hematological diseases (both malignant and non-malignant) in the Department of Hematology at the First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital).
You may qualify if:
- : Patients undergo their first unrelated cord blood transplantation (UCBT) at our institution.
- : Diagnosis of a hematologic malignancy or disorder eligible for UCBT (e.g., acute leukemia, myelodysplastic syndrome, severe aplastic anemia)
- : Willing and able to provide written informed consent.
- : No restrictions on gender, age, or race.
You may not qualify if:
- Participation in an interventional clinical trial investigating prophylactic donor-derived cell infusion (e.g., DLI, MSC) during the study period.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
the First Affiliated Hospital of University of Science and Technology of China
Hefei, Anhui, 230000, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Xiao yu Zhu, ph.D
The First Affiliated Hospital of University of Science and Technology of China
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER GOV
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 20, 2026
First Posted
August 24, 2026
Study Start
October 9, 2025
Primary Completion (Estimated)
November 1, 2026
Study Completion (Estimated)
October 1, 2030
Last Updated
August 24, 2026
Record last verified: 2025-10